Radionuclide-Drug Conjugates (RDCs)
Radionuclide-drug conjugates (RDCs) are one of the most promising development directions for nuclear drug targeted therapy. RDC is composed of targeting element, linker, chelate and radioactive isotope. RDC has advantages in early tumor diagnosis, treatment and postoperative tumor evaluation. The same ligand can be connected to nuclides used for disease diagnosis and treatment respectively, promoting the integration of diagnosis and treatment of RDC drugs. This entry provides molecular intermediates that can be used in the synthesis and research of RDC.
Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products
All Product Categories
-
Radionuclide-Drug Conjugates (RDCs) Related Products (230)
Related Products (230)
-
Radionuclide-Drug Conjugates (RDCs) Isoform Comparison
-
DOTA(tBu3)-PEG4-TFP
0 ImagesCat. No.: HY-167789CAS No.: 2389064-47-3DOTA(tBu3)-PEG4-TFP is a chelating agent and linker conjugate that can be used in the synthesis of radiopharmaceuticals.
-
IPM-N001
0 ImagesCat. No.: HY-P11737IPM-N001 is a carbonic anhydrase IX (CAIX) ligand with a Kd value of <0.0337 nM for hCAIX. When radio-conjugated with 68Ga, IPM-N001 serves as a CAIX-targeted radionuclide tracer. [68Ga]Ga-IPM-N001 exhibits excellent tumor uptake and significantly improves the tumor-to-background ratio in PET/CT imaging studies using OS-RC-2 tumor-bearing mice. IPM-N001 can be used for the research of clear cell renal cell carcinoma.
-
JR11-PEG3-HBED-CC-PSMA-03
0 ImagesCat. No.: HY-P11485JR11-PEG3-HBED-CC-PSMA-03 (Compound 1) is an RDC-related compound containing the chelating agent HBED-CC, the JR11 peptide (SSTR2 antagonist), and the PSMA ligand. JR11-PEG3-HBED-CC-PSMA-03 shows SSTR2-binding affinities and PSMA-binding affinities, with IC50 s of 59.2 nM, 57.0 nM, respectively. JR11-PEG3-HBED-CC-PSMA-03 can be radiolabeled with [68Ga]. [68Ga] radiolabeled JR11-PEG3-HBED-CC-PSMA-03 can be used in diagnostic studies of neuroendocrine differentiated prostate cancer.
-
BQ7859
0 ImagesCat. No.: HY-P10744BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT). BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
-
Lufefolastat Tetraxetan
0 ImagesCat. No.: HY-P12132CAS No.: 2934667-10-2Lufefolastat Tetraxetan is a covalent conjugate of a PSMA-targeted peptide ligand and Tetraxetan (HY-W053583), a DOTA-class chelator. When labeled with 225Ac, Lufefolastat Tetraxetan is applicable to research on prostate-specific membrane antigen (PSMA)-positive metastatic prostate cancer.
-
VHPKQHR
0 ImagesCat. No.: HY-P11887CAS No.: 1174559-81-9VHPKQHR is a peptide-based delivery enhancer that binds to VCAM-1. VHPKQHR enables intracellular internalization of relevant nanomaterials and facilitates the targeted delivery of miRNA inhibitors to inflamed endothelial cells and endothelial cells activated by disturbed flow. When conjugated with magnetic mesoporous silica nanoparticles, VHPKQHR achieves targeted accumulation at atherosclerotic plaque sites. When displayed on the surface of polyelectrolyte complex micelles, VHPKQHR enhances the relevant effects of anti-miR-92a in Apoe-/- mice. When conjugated with ultrasmall superparamagnetic iron oxide nanoparticles, VHPKQHR forms a contrast agent for T1-weighted magnetic resonance imaging. VHPKQHR can be used in research related to atherosclerosis, stenosis and rheumatoid arthritis.
-
RAYZ-8009
0 ImagesCat. No.: HY-P12340CAS No.: 3066113-06-9RAYZ-8009 is a DOTA (HY-W053583)-modified macrocyclic peptide with high affinity for GPC3. The radiolabeled form of RAYZ-8009, [68Ga]Ga-RAYZ-8009, is used for PET imaging studies of hepatocellular carcinoma.
-
Granzyme B contrast agent-1
0 ImagesCat. No.: HY-P11835CAS No.: 3062270-62-3Granzyme B contrast agent-1 is a Granzyme B binder with a Kd value of 1.0 nM. When radiolabeled, Granzyme B contrast agent-1 can be used for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging studies of Granzyme B.
-
Tetraxetan (Standard)
0 ImagesCat. No.: HY-W053583RCAS No.: 60239-18-1Synonyms: DOTA (Standard)Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
-
TCO-GK-PEG4-NHS ester
0 ImagesCat. No.: HY-154802CAS No.: 2307311-19-7TCO-GK-PEG4-NHS ester is an ADC Linker, and can be used for synthesis of [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d. [18F]AlF-NOTA-Tz-TCO-GK-2Rs15d binds with high affinity and immunoreactivity to HER2. TCO-GK-PEG4-NHS ester is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
-
MAIPGG
0 ImagesCat. No.: HY-122939CAS No.: 161876-61-5MAIPGG is a bifunctional chelator and an intermediate in the synthesis of radionuclide drug conjugates (RDCs). MAIPGG can be for the radiolabeling of a variety of monoclonal antibodies with 99mTc or 186Re, which then can be used for radioimmunodetection and radioimmunotherapy of cancer.
-
NH-CH2-CH2-DOTAM
0 ImagesCat. No.: HY-164593CAS No.: 2685840-60-0NH-CH2-CH2-DOTAM is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
Fluorescein-triazole-PEG5-DOTA
0 ImagesCat. No.: HY-W586475Fluorescein-triazole-PEG5-DOTA is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.
-
NOTA-RHAU18
0 ImagesCat. No.: HY-P11486NOTA-RHAU18 is a conjugate of the chelator NOTA and the peptide RHAU18. NOTA-RHAU18 can be used to synthesize the radiolabeled peptide probe [18F]AlF-NOTA-RHAU18. [18F]AlF-NOTA-RHAU18 targets mitochondrial DNA G4. [18F]AlF-NOTA-RHAU18 can be used to visualize and detect solid tumors in homozygous mice. [18F]AlF-NOTA-RHAU18 can also be used in PET imaging studies.
-
3P-RGD2
0 ImagesCat. No.: HY-P11773CAS No.: 1094848-94-8
-
DOTAGA-anhydride (GMP)
0 ImagesCat. No.: HY-W087187GCAS No.: 1375475-53-8DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging.
-
NYM074
0 ImagesCat. No.: HY-183374NYM074 is a carbonic anhydrase IX (CAIX) ligand. NYM074 binds specifically to human CAIX to enable targeted radionuclide delivery. NYM074 supports dual radiolabeling with 68Ga for positron emission tomography (PET) imaging and 177Lu for radionuclide applications. NYM074 can be used for the research of clear cell renal cell carcinoma.
-
Tecnemab K1
0 ImagesCat. No.: HY-P992475Tecnemab K1 is an anti-Melanoma monoclonal antibody. Tecnemab K1 accumulates in metastatic lesions of malignant melanoma and some benign lesions. When radiolabeled, Tecnemab K1 can serve as a radiotracer for malignant melanoma research. The isotype control is Mouse IgG1 kappa, Isotype Control (HY-P99977).
